Evasteo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.90 M
as on 02-01-2025
- Paid Up Capital ₹ 6.40 M
as on 02-01-2025
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.51 M
as on 02-01-2025
- Revenue -3.54%
(FY 2021)
- Profit 126.12%
(FY 2021)
- Ebitda 49.03%
(FY 2021)
- Net Worth 10.92%
(FY 2021)
- Total Assets 19.00%
(FY 2021)
About Evasteo Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.90 M and a paid-up capital of Rs 6.40 M.
The company currently has active open charges totaling ₹9.51 M.
Sreejesh, Ajithkumar Thottathil, Koottilingal Sajeev, and One other member serve as directors at the Company.
- CIN/LLPIN
U52310KL2017PTC050582
- Company No.
050582
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Oct 2017
- Date of AGM
21 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Malappuram, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Evasteo Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Koottilingal Sajeev  | Managing Director | 03-Oct-2017 | Current |
| Byju Mangampully | Managing Director | 03-Oct-2017 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sreejesh | Director | 03-Oct-2017 | Current |
| Ajithkumar Thottathil | Director | 03-Oct-2017 | Current |
Financial Performance of Evasteo Pharmaceuticals.
Evasteo Pharmaceuticals Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 3.54% decrease. The company also saw a substantial improvement in profitability, with a 126.12% increase in profit. The company's net worth Soared by an impressive increase of 10.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Evasteo Pharmaceuticals?
In 2021, Evasteo Pharmaceuticals had a promoter holding of 50.78% and a public holding of 49.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 Sep 2023 | ₹1.47 M | Open |
Hdfc Bank Limited Creation Date: 30 Jun 2023 | ₹1.16 M | Open |
Hdfc Bank Limited Creation Date: 31 May 2023 | ₹1.88 M | Open |
How Many Employees Work at Evasteo Pharmaceuticals?
Evasteo Pharmaceuticals has a workforce of 7 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evasteo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evasteo Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
